TORONTO, June 14, 2022 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) (the “ Company” or “Field Trip“), a global leader in the development and delivery of psychedelic therapies, announced today that it has agreed to increase its participation in the concurrent financing, in support of, and in connection with, the spin-out of its clinics business to Field Trip Health &


Previous articleIncannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea
Next articleField Trip Health Ltd. Schedules Fiscal Fourth Quarter and Full Year 2022 Results Conference Call for Thursday, June 30, 2022 at 8:30 AM ET